337 related articles for article (PubMed ID: 16036053)
1. The risks and benefits of aldosterone antagonists.
Sica DA
Curr Heart Fail Rep; 2005 Aug; 2(2):65-71. PubMed ID: 16036053
[TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.
Sica DA
Methodist Debakey Cardiovasc J; 2015; 11(4):235-9. PubMed ID: 27057293
[TBL] [Abstract][Full Text] [Related]
3. The risks and benefits of therapy with aldosterone receptor antagonist therapy.
Sica DA
Curr Drug Saf; 2007 Jan; 2(1):71-7. PubMed ID: 18690952
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone antagonists in heart failure.
Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
[TBL] [Abstract][Full Text] [Related]
5. What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated?
Sica DA
Curr Cardiol Rep; 2011 Dec; 13(6):520-6. PubMed ID: 21993610
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
7. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
[TBL] [Abstract][Full Text] [Related]
8. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
9. Review article: eplerenone: an underused medication?
Abuannadi M; O'Keefe JH
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
Struthers A; Krum H; Williams GH
Clin Cardiol; 2008 Apr; 31(4):153-8. PubMed ID: 18404673
[TBL] [Abstract][Full Text] [Related]
11. New therapy update. Inspra (eplerenone tablets).
Kloner RA
Congest Heart Fail; 2003; 9(6):341-2. PubMed ID: 14688507
[No Abstract] [Full Text] [Related]
12. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
[TBL] [Abstract][Full Text] [Related]
13. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
Barnes BJ; Howard PA
Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
[TBL] [Abstract][Full Text] [Related]
14. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
[TBL] [Abstract][Full Text] [Related]
15. Eplerenone and chronic heart failure. No comparison with spironolactone.
Prescrire Int; 2013 Jun; 22(139):148-9. PubMed ID: 23866347
[TBL] [Abstract][Full Text] [Related]
16. Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency.
Hu Y; Carpenter JP; Cheung AT
Anesth Analg; 2002 Jul; 95(1):39-41, table of contents. PubMed ID: 12088939
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
18. The clinical pharmacology of eplerenone.
Muldowney JA; Schoenhard JA; Benge CD
Expert Opin Drug Metab Toxicol; 2009 Apr; 5(4):425-32. PubMed ID: 19379127
[TBL] [Abstract][Full Text] [Related]
19. [Aldosterone receptor blockade after acute myocardial infarction with heart failure].
Bauersachs J; Ertl G
Med Klin (Munich); 2006 Jun; 101(6):458-66. PubMed ID: 16767569
[TBL] [Abstract][Full Text] [Related]
20. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
